Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HT31-1 in Healthy Volunteers
NCT07449572Phase 1Recruiting
- Sponsor
- Healthcare Technology Innovation Centre
- Start
- May 2026
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HT31-1 in acute respiratory distress syndrome (ARDS) (6 cohorts), sponsored by Healthcare Technology Innovation Centre. Primary endpoints: Incidence of Adverse Events and Serious Adverse Events at 28 days and Dose-limiting toxicities at 28 days. Started May 2026; status: recruiting.
02
Drugs
HT31-1
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT07449572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07449572.